Fig. 5: Systemically delivered d-pleurocidin-KR is effective in a murine model of EMRSA-15 lung infection. | Communications Biology

Fig. 5: Systemically delivered d-pleurocidin-KR is effective in a murine model of EMRSA-15 lung infection.

From: A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy

Fig. 5: Systemically delivered d-pleurocidin-KR is effective in a murine model of EMRSA-15 lung infection.

C57Bl6J mice, challenged with 1 × 106 CFU/mouse EMRSA-15 in tryptic soy agar beads, were treated with vancomycin or d-pleurocidin-KR in three intravenous doses at 4, 24 and 30 h post infection to achieve the cumulative doses indicated. Bacterial burden in the lung (a), weight loss over the 48-h infection period (b) and BAL cells (c–e) and cytokines (f–i) reveal the effect of each intervention. Data presented are an aggregate of two independent repeats, each with control groups (n = 6) and peptide treatment groups (n = 4). Significance is indicated relative to the saline vehicle (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Bars represent mean and SEM.

Back to article page